Politics and Policy

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

Eosinophilic esophagitis is progressive disease driven in part by type 2 inflammation. Dupixent is the first treatment for children as young as 1 year old.

Balversa targets FGFR3 genetic alterations and is approved as a second-line treatment for in adult patients with metastatic urothelial carcinoma.

Last year saw the approval of several firsts, including the first vaccines to prevent respiratory syncytial virus in older adults and infants and a first vaccine to prevent the mosquito-borne virus chikungunya.

HyQvia is now available a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy, which can lead to weakness and loss of feeling in the arms and legs.

With a cost of $2.2 million, Casgevy is a CRISPR/Cas9 gene-edited cell therapy that is now also approved to treat beta thalassemia. It was approved to treat sickle cell disease in December 2023.

Tivdak was granted accelerated approval in September 2021 to treat patients with recurrent or metastatic cervical cancer. The goal date for full approval is May 9, 2024.

The FDA cited issues with a third-party manufacturing company. Zolbetuximab is being reviewed to treat patients with stomach cancer.

Zelsuvmi, a first-in-class topical treatment approved for patients with molluscum contagiosum, will be available in the second half of 2024.

If approved, Accord’s biosimilar would treat several autoimmune conditions and would be launched no later than May 15, 2025

Loqtorzi has a wholesale acquisition cost of $8,892.03 per single-use vial.

Wainua is approved to treat patients with hereditary transthyretin-mediated amyloid polyneuropathy and can be self-administered via an auto-injector.

This is the first treatment for patients with primary immunoglobulin A nephropathy to be granted full approval.

This is the second complete response letter for gefapixant, and FDA officials said the application did not provide evidence of effectiveness.

Outlook Therapeutics plans to begin a study in the first quarter of 2024 to address the issues identified in a FDA complete response letter. If approved, Lytenava would be the only bevacizumab product to specifically treat age-related macular degeneration.

In other generic news, the FDA has approved generics of the osteoporosis drug Forteo and Amneal is developing a generic version of Vascepa.

Zoryve foam will have the same wholesale acquisition cost as the cream version: $858 per tube.

The FDA cited issues related to an inspection of Checkpoint Therapeutics’ third-party contract manufacturing organization.

The price for of Adbry is $1,810.87 for a two pack of syringes.

Welireg is now also indicated for patients whose renal cell carcinoma has progressed after treatment with PD-1 or PD-L1 inhibitor and a TKI therapy.

The FDA has set a target date of June 12, 2024, for tarlatamab to treat adult patients with advanced small cell lung cancer. If approved, it would be the first bispecific antibody for a solid tumor.

The report from the American Medical Association evaluates health insurer market share at the metropolitan statistical area level and national level.

The application for midomafetamine is the first NDA submission for any psychedelic-assisted therapy.

Marstacimab is being reviewed to prevent or reduce the frequency of bleeding episodes in people with hemophilia A or B. The FDA has set an action date in the first quarter of 2024.

The FDA has approved the gene therapies Lyfgenia and Casgevy to treat patients with sickle cell disease. Casgevy is the first FDA-approved gene therapy to use the CRISPR gene editing technology.

If approved, elafibranor would be a second-line treatment for patients with primary biliary cholangitis. The Prescription Drug User Fee Act action date is June 10, 2024.

Augtyro, approved last month, launched with a month wholesale acquisition $29,000 for patients with ROS1-positive non-small cell lung cancer.

Fabhalta was approved to treat patients with paroxysmal nocturnal hemoglobinuria and will have a wholesale acquisition cost of $550,000 per year.